Abstract
Using chimeric resistant MRL/lpr mice, we have very recently established a novel BMT method, called intrabone marrow (IBM)-BMT. IBM-BMT is far superior to conventional intravenous-BMT (IV-BMT), since it can be used to treat autoimmune diseases in MRL/lpr mice. In addition, we have established a new method for bone marrow cell-harvesting, called Perfusion Method (PM). BMCs collected by the PM contain both pluripotent hemopoietic stem cells and mesenchymal stem cells, but not T cells due to peripheral blood contamination. Therefore, when PM + IBM-BMT are carried out, neither GvHD nor graft reject occurs. This method should therefore become a valuable regeneration therapy for osteoporosis, emphysema, etc.
